U.S., June 27 -- ClinicalTrials.gov registry received information related to the study (NCT07670312) titled 'Evaluation of XYA02 in Patients With Advanced Solid Tumors' on June 01.
Brief Summary: This study will evaluate the safety, tolerability, and efficacy of XYA02 in participants with advanced solid tumors.
Study Start Date: July 15
Study Type: INTERVENTIONAL
Condition:
MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors
Non-Small Cell Lung Cancer
Ovarian Cancer
GEJ Adenocarcinoma
Colorectal Cancer
Pancreatic Adenocarcinoma
Intervention:
BIOLOGICAL: XYA02
IV infusion
Recruitment Status: NOT_YET_RECRUITING
Sponsor: XYone Therapeutics, Inc
Published by HT Digital Content Services with permission from Health Daily ...